261 related articles for article (PubMed ID: 26219615)
1. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
3. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
4. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
5. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
Greillier L; Tomasini P; Barlesi F
Ther Adv Respir Dis; 2016 Oct; 10(5):485-91. PubMed ID: 27340254
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
8. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
10. [Current progression of bevacizumab in advanced non-small cell lung cancer].
Chu TQ; Chen JH; Han BH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):793-800. PubMed ID: 30392346
[TBL] [Abstract][Full Text] [Related]
11. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Reinmuth N; Heigener D; Reck M
Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
[TBL] [Abstract][Full Text] [Related]
12. Targeting angiogenesis in squamous non-small cell lung cancer.
Piperdi B; Merla A; Perez-Soler R
Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
[TBL] [Abstract][Full Text] [Related]
13. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
14. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
16. International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes.
de Marinis F; Bria E; Ciardiello F; Crinò L; Douillard JY; Griesinger F; Lambrechts D; Perol M; Ramalingam SS; Smit EF; Gridelli C
J Thorac Oncol; 2016 Jul; 11(7):1153-69. PubMed ID: 27063293
[TBL] [Abstract][Full Text] [Related]
17. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
18. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.
Crinò L; Metro G
Eur Respir Rev; 2014 Mar; 23(131):79-91. PubMed ID: 24591665
[TBL] [Abstract][Full Text] [Related]
20. Targeting angiogenesis in advanced non-small cell lung cancer.
Lammers PE; Horn L
J Natl Compr Canc Netw; 2013 Oct; 11(10):1235-47. PubMed ID: 24142825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
